Insights On Upstream Manufacturing

  1. Precision Expression: Accelerating Complex Biotherapeutic Production In CHO Cells 3/26/2026

    Learn how this advanced strategy accelerates development timelines while delivering consistently high titers, robust manufacturability, and enhanced product quality.

  2. Mammalian Cell Line Development 3/26/2026

    Explores how modern cell line engineering boosts speed, stability, and scalability across biologics, with practical insights to cut risk and improve readiness for downstream development.

  3. Systematic Strategy To Reduce The Cost Of Goods Sold 3/26/2026

    Learn key ways to cut biologics manufacturing costs through smarter process design, material choices, and supply resilience — driving more efficient, reliable, and commercially sustainable production.

  4. WuXia293Stable: Express What CHO Can't 3/26/2026

    Discover a modern 293‑based expression system built for higher purity, controlled glycosylation, and improved activity, offering a new option for teams developing complex or next‑generation biologics.

  5. Five Reasons To Choose Single-Use Bioreactors 3/25/2026

    Explore five key advantages of single-use bioreactors, including scalable design, homogeneous mixing, broad chemical compatibility, and streamlined seed train processes for bioproduction success.

  6. Criteria For Effective Bioprocess Scale-Up 3/25/2026

    Discover four essential bioprocess scale-up criteria and how each balances hydrodynamics, shear, and mass transfer across manufacturing scales.

  7. Demonstrating Bioprocess Scalability Through Platform Consistency 3/25/2026

    Explore how a unified bioreactor design enables consistent process performance from bench to production, minimizing scale-up risk while maintaining cell growth and yield.

  8. Unlock The Potential Of GPEx Lightning Accelerate Your HEK Cell Line Development 3/25/2026

    Discover how an advanced cell line development platform now supports HEK cells alongside CHO, enabling rapid, scalable production of complex biologics while saving up to 12 weeks on development timelines.

  9. A Highly Productive, Chemically Defined Exosome Media System 3/24/2026

    Explore how chemically defined media and optimized bioreactor protocols increase exosome yields 40-fold while reducing commercial manufacturing costs from $10,000 to under $1,000 per dose.

  10. Where MSCs Go When Injected And Why It Matters 3/24/2026

    Understand why IV-delivered MSCs undergo rapid apoptosis in lung tissue while locally implanted cells survive as programmable therapeutic factories—and how this knowledge enables rational MSC engineering.